Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience
نویسندگان
چکیده
An advance of Hodgkin lymphoma (HL) diagnostic and treatment protocols promoted between fatal high-curative disease. Modern programs can reach many-year survival rate in 8097% even patients with advanced (IIIIV) HL stages unfavorable prognostic factors pre- sence. Nevertheless, relapses refractory (r/r) appears 830% depend on scheme, comorbi- dity. Second-line therapy (ViGePP ICE) is a common platform for r/r pediatric patients, but results 3-year relapse-free (RFS) not to exceed 7075%. For increase RFS as combinatorial partners schemes ViGePP ICE add monoclonal antibodies (brentuximab vedotine) immune chekpoint inhibitors (nivolumab), cell (auto-/allogenic stem transplantation) genetically engineered (CAR-T) products. In the current issue literature own experience presented. It showed, that inclusion brentuximab vedotine scheme increased up 8311.2%.
منابع مشابه
Treatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children
Hodgkin lymphoma (HL) accounts for about 10% of all childhood cancers. Five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. The current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. T...
متن کاملBrentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after...
متن کاملtreatment of newly diagnosed and relapsed hodgkin lymphoma in children
hodgkin lymphoma (hl) accounts for about 10% of all childhood cancers. five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. the current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ??????????? ?????????
سال: 2022
ISSN: ['2663-466X', '2410-2792']
DOI: https://doi.org/10.26442/18151434.2022.3.201816